Literature DB >> 3511692

Oslo Study Diet and Antismoking Trial. Results after 102 months.

I Hjermann, I Holme, P Leren.   

Abstract

The five year (60-month) results from the Oslo Study Diet and Antismoking Trial were published in the Lancet in December 1981. The trial involved 1,232 healthy men, aged 40 to 49 years, at high risk for coronary heart disease, with serum cholesterol values in the range of 7.5 to 9.8 mmol/liter (enzymatic method: 6.9 to 9.0, mean value 7.8 mmol/liter). Eighty percent of the men were daily cigarette smokers at the start of the study, and all participants were normotensive, i.e., systolic blood pressure was less than 150 mm Hg. Subjects were randomly assigned to either a control or intervention group. Follow-up visits were scheduled every six months for the intervention group and yearly for the control group. Once the trial was completed, the regular six-month follow-up visits were discontinued, but eight to nine years (96 to 108 months) after the start of the trial, participants were called for a new follow-up. Risk factors were recorded, and clinical events were diagnosed according to the same procedure as during the trial. The mean serum cholesterol levels in the intervention group remained unchanged three years after the end of the trial, but the cholesterol levels in the control group declined. Daily cigarette smoking increased in the intervention group but remained stable in the control group. At the new follow-up, the difference in incidence of fatal and nonfatal myocardial infarction and sudden coronary death was the same as at the end of the trial three years earlier, yielding significant differences between the two groups for sudden death, total coronary death, and total coronary events. Although the study was not designed to show differences in total mortality, this difference became marginally significant, with 19 deaths in the intervention group and 31 in the control group. It is concluded that although net differences in risk factors between the two groups had been reduced during the three years after the regular intervention period, the significant difference in coronary events and sudden death was maintained.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511692     DOI: 10.1016/0002-9343(86)90154-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  19 in total

1.  The cholesterol controversy.

Authors:  A S Truswell
Journal:  BMJ       Date:  1992-04-04

2.  Dietary and pharmacologic management of cholesterol.

Authors:  B M Rifkind
Journal:  Tex Heart Inst J       Date:  1990

Review 3.  Fatty acid composition of the diet: impact on serum lipids and atherosclerosis.

Authors:  N Zöllner; F Tatò
Journal:  Clin Investig       Date:  1992-11

4.  Smoking, smoking cessation, and risk of cardiovascular disease.

Authors:  Peter W F Wilson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

Review 5.  How much dietary fat in therapeutic nutrition?

Authors:  V Simko
Journal:  Bull N Y Acad Med       Date:  1990 Mar-Apr

Review 6.  Multiple risk factor interventions for primary prevention of coronary heart disease.

Authors:  S Ebrahim; A Beswick; M Burke; G Davey Smith
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

7.  Quality of life is not negatively affected by diet and exercise intervention in healthy men with cardiovascular risk factors.

Authors:  M L Hellénius; C Dahlöf; H Aberg; I Krakau; U de Faire
Journal:  Qual Life Res       Date:  1995-02       Impact factor: 4.147

Review 8.  The independent roles of diet and serum lipids in the 20th-century rise and decline of coronary heart disease mortality.

Authors:  R H Rosenman
Journal:  Integr Physiol Behav Sci       Date:  1993 Jan-Mar

9.  Cardiovascular risk determination: discrepancy between total cholesterol evaluation and two compound laboratory indices in Norway.

Authors:  J E Berg; A T Høstmark
Journal:  J Epidemiol Community Health       Date:  1994-08       Impact factor: 3.710

10.  Failure to reduce cholesterol as explanation for the limited efficacy of antihypertensive treatment in the reduction of CHD. Examination of the evidence from six hypertension intervention trials.

Authors:  S Heyden; K A Schneider; G J Fodor
Journal:  Klin Wochenschr       Date:  1987-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.